CER-320

CER-320 is an investigational HDL-based drug-delivery candidate developed by Cerenis Therapeutics (now part of Abionyx Pharma) as part of a program to use reconstituted high‑density lipoprotein (HDL) nanoparticles as targeted carriers for therapeutic payloads, including in immuno-oncology. It is designed to exploit HDL’s natural interactions with vascular and immune compartments to deliver active agents to specific tissues or cells, but detailed public information on its exact molecular composition, payload, targets, and indications has not been disclosed. Available information positions CER-320 primarily as a platform-derived, HDL-mimetic, nanoparticle-based therapy rather than a conventional small molecule or antibody.